In July 2026, Science Corporation's retinal chip achieved CE certification in the EU, marking a significant milestone in brain-computer interface commercialization. While Neuralink continues to address safety concerns for human trials, Science Corporation, founded by a former co-founder, is set to launch its first commercial implants in Germany.
This development is crucial as it signifies a shift from theoretical concepts of brain-computer interfaces to practical medical applications. The Prima retinal chip, measuring just 2x2 mm and powered by near-infrared light through smart glasses, has shown promising clinical results, with 84% of patients recovering reading abilities.
Looking ahead, 2026 is anticipated to be a pivotal year for brain-computer interfaces, with regulatory frameworks being established in China and significant advancements in both invasive and non-invasive devices. Science Corporation aims to complete dozens of commercial implants this year and targets around 200 next year, with revenue from the Prima chip expected to fund the development of next-generation neural interfaces.
Editor's Note
The rapid advancements in brain-computer interfaces (BCIs) highlight a transformative shift in medical technology, particularly in addressing neurological disorders. As companies like Science Corporation and their Chinese counterparts push the boundaries of BCI applications, the industry is witnessing a convergence of engineering and medical science that could redefine patient care and rehabilitation strategies.
Leave a comment